Fluticasone and cyclophosphamide towards the track of personalized medicine

Abstract

Personalized medicine or precision medicine is a preventive standard that splits people into distant groups with pharmaceutical accord, method, mediation and products are being made to measure to the entity case based on their forecast response or hazard of infection. The Promise of Personalized Medicine, “therapy with the right drug at the right dose in the right patient” is a description of how personalized medicine will affect the future of treatment. A form of a patient's heredity abnormality can guide the choice of drugs or treatment custom to physicians that will diminish the harmful side effects or ensure the more successful outcomes. Personalized medicine reduces the cost of drugs, adverse drug reactions to patients and Increasing patient compliance with treatment. As Fluticasone and cyclophosphamide has high inter-individual variability, genetic polymorphism and population pharmacokinetics was studied, in-order to provide optimum dose for all individuals. Genetic Polymorphism associated with fluticasone was ABCB1 and CYP3A4*22, whereas genetic polymorphism associated with cyclophosphamide was CYP2B6 and GSTP1. Population Pharmacokinetics of fluticasone was done in different places using the co-factors such as genetic polymorphism, Alcohol consumption, weight, Height, Age and Smoking, whereas population pharmacokinetics of cyclophosphamide was done using co-factors such as Genetic polymorphism, Age, Body weight, Liver dysfunction. From the information obtained from population pharmacokinetics, a personalized chart for fluticasone and cyclophosphamide was constructed. In this study, genetic polymorphism and population pharmacokinetics of Fluticasone and Cyclophosphamide towards Personalized medicine was carried out.